Insider Selling: Taysha Gene Therapies (NASDAQ:TSHA) CFO Sells 23,849 Shares of Stock

Taysha Gene Therapies, Inc. (NASDAQ:TSHA) CFO Kamran Alam sold 23,849 shares of the stock in a transaction dated Monday, January 26th. The shares were sold at an average price of $4.61, for a total value of $109,943.89. Following the completion of the sale, the chief financial officer owned 1,443,786 shares of the company’s stock, valued at approximately $6,655,853.46. This trade represents a 1.62% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website.

Kamran Alam also recently made the following trade(s):

• On Friday, January 23rd, Kamran Alam sold 78,968 shares of Taysha Gene Therapies stock. The stock was sold at an average price of $4.75, for a total value of $375,098.00.

Taysha Gene Therapies Stock Performance

Shares of NASDAQ TSHA traded up $0.04 during midday trading on Tuesday, hitting $4.76. 1,384,585 shares of the company’s stock were exchanged, compared to its average volume of 2,812,476. Taysha Gene Therapies, Inc. has a twelve month low of $1.05 and a twelve month high of $6.02. The company has a debt-to-equity ratio of 0.23, a current ratio of 10.48 and a quick ratio of 10.48. The firm has a market cap of $1.30 billion, a P/E ratio of -14.42 and a beta of 1.02. The stock’s 50 day moving average price is $5.08 and its 200-day moving average price is $4.07.

Taysha Gene Therapies (NASDAQ:TSHA) last posted its quarterly earnings results on Tuesday, November 4th. The company reported ($0.09) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.09). Taysha Gene Therapies had a negative net margin of 1,144.97% and a negative return on equity of 67.26%. Equities research analysts anticipate that Taysha Gene Therapies, Inc. will post -0.35 EPS for the current year.

Hedge Funds Weigh In On Taysha Gene Therapies

Institutional investors have recently added to or reduced their stakes in the company. Vanguard Group Inc. raised its holdings in shares of Taysha Gene Therapies by 17.9% during the third quarter. Vanguard Group Inc. now owns 12,849,613 shares of the company’s stock valued at $42,018,000 after purchasing an additional 1,955,486 shares during the last quarter. Octagon Capital Advisors LP grew its stake in Taysha Gene Therapies by 17.7% in the 2nd quarter. Octagon Capital Advisors LP now owns 12,592,500 shares of the company’s stock worth $29,089,000 after acquiring an additional 1,892,500 shares in the last quarter. Jefferies Financial Group Inc. boosted its position in Taysha Gene Therapies by 4,105.3% during the 2nd quarter. Jefferies Financial Group Inc. now owns 10,313,733 shares of the company’s stock valued at $23,825,000 after acquiring an additional 10,068,479 shares in the last quarter. Vestal Point Capital LP increased its holdings in shares of Taysha Gene Therapies by 83.3% during the third quarter. Vestal Point Capital LP now owns 5,500,000 shares of the company’s stock valued at $17,985,000 after acquiring an additional 2,500,000 shares in the last quarter. Finally, Polar Capital Holdings Plc boosted its holdings in shares of Taysha Gene Therapies by 5.9% in the 3rd quarter. Polar Capital Holdings Plc now owns 5,293,879 shares of the company’s stock valued at $17,311,000 after acquiring an additional 293,879 shares during the last quarter. Institutional investors own 77.70% of the company’s stock.

Wall Street Analyst Weigh In

Several equities research analysts have recently commented on the stock. Needham & Company LLC restated a “buy” rating and issued a $10.00 target price on shares of Taysha Gene Therapies in a research note on Friday, October 17th. Cantor Fitzgerald restated an “overweight” rating and set a $13.00 price objective on shares of Taysha Gene Therapies in a research note on Friday, November 14th. JMP Securities set a $8.00 target price on shares of Taysha Gene Therapies in a research note on Wednesday, November 5th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Taysha Gene Therapies in a research note on Monday, December 29th. Finally, Citizens Jmp boosted their target price on shares of Taysha Gene Therapies from $6.00 to $8.00 and gave the stock a “market outperform” rating in a research note on Wednesday, November 5th. One investment analyst has rated the stock with a Strong Buy rating, eleven have given a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, Taysha Gene Therapies currently has a consensus rating of “Moderate Buy” and a consensus price target of $10.67.

Taysha Gene Therapies Company Profile

Taysha Gene Therapies, Inc (NASDAQ: TSHA) is a clinical-stage biotechnology company focused on developing gene therapies for rare monogenic diseases of the central nervous system. Using a proprietary adeno-associated viral (AAV) vector platform, the company engineers novel capsids and regulatory elements to optimize delivery and expression of therapeutic genes. Its pipeline features lead programs such as TSHA-102 for GM2 gangliosidoses (Tay–Sachs and Sandhoff diseases), TSHA-101 for GM1 gangliosidosis and TSHA-103 for aromatic l-amino acid decarboxylase (AADC) deficiency, alongside earlier-stage candidates targeting other life-threatening pediatric CNS disorders.

Founded in 2019 and headquartered in Dallas, Texas, Taysha Gene Therapies completed its initial public offering in May 2021.